$IMCR News

Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes

Immunocore Hldgs Q2 2026 Earnings Call Transcript

Immunocore: Advanced Cutaneous Melanoma Data Catalysts Feel Crucial

Immunocore Holdings plc (IMCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma

Immunocore Holdings Announces Achievement Of Target Patient Enrollment In TEBE-AM Clinical Trial; Topline Overall Survival Data Expected As Early As End Of 2026

Will Kimmtrak Continue to Aid IMCR's Growth Through the Rest of 2026?

JP Morgan Reinstates Overweight on Immunocore Holdings, Announces $50 Price Target

Wall Street Analysts See a 77.91% Upside in Immunocore (IMCR): Can the Stock Really Move This High?

How Strong H1 Profits and Kimtrak Survival Data At Immunocore (IMCR) Have Changed Its Investment Story

Immunocore Holdings plc 2026 Q2 - Results - Earnings Call Presentation

Immunocore Q2 Earnings Call Highlights

Immunocore Holdings PLC (IMCR) (Q2 2026) Earnings Call Highlights: Kimtrak Growth and Pipeline ...

Immunocore Holdings plc (IMCR) Q2 2026 Earnings Call Transcript

Immunocore Holdings PLC (IMCR) (Q2 2026) Earnings Call Highlights: Strong Kimtrak Growth and ...

Immunocore (NASDAQ:IMCR) Q2 Revenue Beats but EPS Misses, Shares Tumble

Immunocore reports second quarter financial results and provides a business update

Immunocore Hldgs Q2 EPS $(0.02) Misses $0.02 Estimate, Sales $115.927M Beat $110.374M Estimate

Mizuho Maintains Neutral on Immunocore Holdings, Raises Price Target to $35

Immunocore to report second quarter 2026 financial results and host call on August 6, 2026